rAAV-based gene therapy (Baker IDI Heart & Diabetes Institute/Monash University/University of Melbourne)

N/A

Report date: 2025/03/19 11:42:25

Base Information

Drug NamerAAV-based gene therapy (Baker IDI Heart & Diabetes Institute/Monash University/University of Melbourne)
Drug Alias NameN/A
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Adeno-associated virus vector
Mechanisms of ActionMothers against decapentaplegic homolog 7 stimulantsActivin receptor type-2B inhibitors
TargetsMothers against decapentaplegic homolog 7Activin receptor type-2B
Therapy Area/IndicationsCachexia
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryAustralia and New Zealand
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesBaker Idi Heart And Diabetes Institute Holdings Ltd
China Registration ClassN/A

Develop Information

Active CompaniesBaker Idi Heart And Diabetes Institute Holdings LtdMonash UniversityUniversity Of Melbourne
Inactive CompaniesN/A
Active IndicationsCachexia
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A